Summary This study shows that combinations of bryostatin 1, a novel modulator of protein kinase C currently under clinical evaluation, with the anti-oestrogenic agent tamoxifen caused a large synergistic enhancement of growth inhibition in P388 cells in vitro. The growth-inhibitory effects of bryostatin 1 in the presence of non-inhibitory concentrations of tamoxifen were increased by approximately 200-fold, whereas growth inhibition by tamoxifen in the presence of non-inhibitory concentrations of bryostatin 1 were increased over 30-fold. These data have been confirmed by isobologram analysis. The precise mechanism underlying this effect is unknown, although preliminary data implicating protein kinase C is presented. The magnitude of this synergistic effect, together with evidence of clinical responses seen when these agents were given sequentially in ovarian cancer, merits further study.
Bryostatin 1 is a macrocyclic lactone isolated from the marine invertebrate Bugula neritina, a member of the phylum Ectoprocta (Pettit et al, 1982) . Bryostatin 1 exerts a wide variety of biological effects, including antineoplastic activity, immunoenhancing effects and haemopoietic stimulation. Bryostatin 1 showed significant activity in vitro against several cell lines, including leukaemia, lymphomas, melanoma, lung and renal tumours (Pettit et al, 1982; Dale and Gescher, 1989; Hornung et al, 1992) . Although the precise mechanism of action of bryostatin 1 is unknown, it is believed that the agent modulates protein kinase C (PKC) (Berkow and Kraft, 1985) .
The PKC proteins are a family of serine-threonine kinases that are involved in a range of cellular processes, including growth and differentiation (Azzi et al, 1992; Gescher, 1992 ). The precise mechanism by which activation of PKC can elicit such a variety of biological responses is unknown. However, it is likely that differences in activation, down-regulation and intracellular translocation of individual PKC isoforms after activation may give rise to this diversity of effects.
Bryostatin 1 shares many of the biological effects of known activators of PKC, such as the phorbol esters (Dale and Gescher, 1989) . It has been shown that cells made resistant to bryostatin 1 show reduced expression of PKC and decreased PKC activity (Prendiville et al, 1994) . A comparison of the effects of bryostatin 1 and the phorbol esters, however, shows several important differences. Bryostatin 1 does not induce differentiation in human bronchial epithelium (Jetten et al, 1989) and is not a tumour promoter. Indeed, bryostatin 1 has been shown to inhibit the tumour-promoting properties of phorbol esters (Hennings et al, 1987) . These differences may arise because of differential activation, intracellular distribution or stabilization of the various isoforms that make up the PKC family.
Tamoxifen, a widely used anti-oestrogen, is also known to interact with PKC. However, unlike bryostatin 1, tamoxifen is an inhibitor of these kinases (O'Brian et al, 1988) .
A phase I trial of bryostatin 1 (Jayson et al, 1995) showed responses in ovarian cancer. After relapse, these patients showed further responses to tamoxifen. These observations were unexpected and led to this investigation into a possible interaction between these agents. The clinical situation cannot be easily emulated, and a simplified study combining these agents in vitro was therefore undertaken. Both these agents are known to modulate PKC, and therefore the role of these kinases was also investigated.
MATERIALS AND METHODS
The cell lines used in this study were P388 (murine lymphocytic leukaemia), P388 BR/D, a bryostatin-resistant cell line derived from the parental P388 cells (Prendiville et al, 1994) , A2780 human ovarian and the human breast cell lines, MCF-7 and BT-20. These had been screened for mycoplasma and were free of infection. All chemicals and drugs were obtained from reputable sources and were of the highest quality available. Bryostatin 1 was isolated in the laboratory by one of the authors (GR Pettit). Oestrogen and progesterone receptor levels were measured by the clinical endocrinology service at the Christie Hospital, Manchester, UK, using commercial ERICA and PgRICA kits (Abbott Laboratories, UK).
Growth inhibition was determined using the MTT assay (Vistica et al, 1991) with, unless otherwise stated, continuous exposure to the drug. The analysis of the effect of drug combinations was carried out by the isobologram method (Steel and Peckham, 1979) .
PMA (phorbol 12-myristate 13-acetate)-activated PKC activity was assayed by phosphorylation of an acetylated peptide based on myelin basic protein, Ac-MBP (4-14), (Yashuda et al, 1990) , as described previously (Prendiville et al, 1994) . P388 cells (approximately 1 x 107 per assay) were rapidly pelleted, washed with icecold phosphate-buffered saline, resuspended in ice-cold extraction buffer (20 mm Tris, pH 7.5, 0.5 mM EDTA, 0.5% Triton X-100 and (Steel and Peckham, 1979) 25 ug ml-1 aprotinin and leupeptin) and sonicated. Figure 1 shows that 1 ,ug ml-1 tamoxifen potentiated the effect of bryostatin 1 more than 200-fold while 1 ng ml-' bryostatin 1 potentiated the effect of tamoxifen by more than 30-fold. This isobologram shows the effects of combinations of bryostatin 1 and tamoxifen. The data are the IC50 concentrations of each drug both individually (bryostatin, 39 ng ml-'; tamoxifen, 4 jg ml-I) and in combination. If the agents were simply acting additively then the combination of drug concentrations that would cause a 50% decrease in cell growth would fall on a straight line joining the individual IC50 values. However, nonlinearity of survival curves generates an 'envelope of additivity' (shaded area). If a combination of agents shows synergy (as in this case), the curve will lie below the envelope of additivity. It was also demonstrated that the synergistic effect was maintained even when drugs were given sequentially at times up to 24 h apart (data not shown).
No synergy between tamoxifen and bryostatin 1 was observed when the P388BR/D (bryostatin-l-resistant) cells, which have reduced PKC expression, were incubated with tamoxifen in the presence of bryostatin 1 at concentrations up to 100 ng ml'. (IC50 tamoxifen alone, 5.4 gg ml-1; IC50 tamoxifen in the presence of 100 ng ml bryostatin 1, 5.1 ,ug ml-') ( Table 2) .
The PKC activator phorbol 12-myristate 1 3-acetate (PMA) also potentiated the growth inhibitory effects of tamoxifen (Table 2) . This potentiation (25-fold) was similar with bryostatin I (34-fold) under similar experimental conditions. However, tamoxifen at the non-inhibitory concentration of 1 gg ml-' caused only a modest (four-fold) increase in the growth-inhibitory effects of PMA compared with that observed with bryostatin 1 (200-fold, Table 2 ). Interestingly, the PKC inhibitor staurosporine did not enhance the activity of bryostatin 1 or tamoxifen ( Table 2) .
The roles of oestrogen and oestrogen receptors in this synergy were studied. Two cell lines with different oestrogen receptor status (MCF-7 receptor positive and BT-20 receptor negative) were shown to have differential responses to tamoxifen (IC, 0.7 jig ml' and 3.3 jg ml-' respectively) but were insensitive to the growthinhibitory effects of bryostatin 1 (IC50 > 100 ng ml-'). Simultaneous incubation with tamoxifen (1 jg ml-') did not result in growth inhibition by bryostatin 1 in either cell line at concentrations up to 100 ng ml-'. Combinations of oestrogen and bryostatin 1 also showed no enhancement of growth inhibition in P388 cells. Furthermore, an analysis of P388 cells showed no detectable oestrogen or progesterone receptor. These data provide evidence that oestrogen and the oestrogen receptor are not involved in the synergy.
The role of PKC in the enhancement of drug sensitivity was investigated. PKC activity attributable to PMA was measured 90 min and 24 h after treatment with tamoxifen and bryostatin 1. The concentrations of drugs used were chosen to produce a range of growth-inhibitory effects when given either as single agents in combination (Table 3 ). All combinations and each individual drug ablated PKC activity 90 min after addition of drug. However, the PKC activity in cells treated with non-or weakly inhibitory concentrations of drugs showed elevated PKC activities 24 h after treatment (Table 3 ). This elevation of PKC activity was substantial and ranged from a 28-fold increase (bryostatin 1, 0.1 ng ml-') to a 90-fold increase for tamoxifen (1 jig ml-'). The relatively noninhibitory combination of drugs (bryostatin 0.1 ng ml-', tamoxifen 1 jig ml') showed an almost 160-fold increase in PKC activity at 24 h compared with untreated (control) cells, whereas more growthinhibitory combinations showed a loss of PKC activity at 24 h.
DISCUSSION
Bryostatin 1 is believed to act by modulation of cell signalling via an interaction with PKC (Berkow and Kraft, 1985) . PKC is an attractive target for cancer chemotherapy as these kinases play a central role in many cellular processes, including cell growth and division. PKC consists of a family of serine-threonine kinases that are activated by a number of factors. Activation is followed by translocation and down-regulation. The fate of individual isoforms is cell line dependent and influenced by a number of parameters, including the nature of the activating species.
Phase I trials of bryostatin 1 were undertaken in Manchester and Oxford, UK, under the sponsorship of the Cancer Research Campaign (Philip et al, 1993; Prendiville et al, 1993; Jayson et al, 1995) . In the third of these phase I trials, bryostatin 1 was given as a 24-hour intravenous infusion, weekly for 8 weeks. The doselimiting toxicity was myalgia, and this limited the recommended dose for phase II evaluation to 25 jgml-2 per week. Four responses were seen (n = 19), with two (one partial and one minor) in women who had been heavily pretreated with chemotherapy for advanced ovarian carcinoma. Disease progression was noted in these patients 4 months and 6 months after completion of bryostatin 1 treatment. The patient who showed the minor response to bryostatin 1 was treated with intravenous paclitaxel, which afforded a further partial response of 4 months duration. Both patients were subsequently treated with tamoxifen (20 mg day-' for 6 months); the patients who had initially showed a partial response to bryostatin 1 also achieved a radiological partial response to tamoxifen of 14 months duration, while the second patient also showed stabilization of disease for 10 months.
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The response rate in patients with chemoresistant ovarian carcinoma treated with tamoxifen (20 mg day-') is 7% (Ahlgren et al, 1993) . Thus, the responses, initially to bryostatin 1 and subsequently to tamoxifen, seen in these patients, although anecdotal, were unexpected and prompted this investigation into combining these agents. The clinical situation, in which bryostatin 1 and tamoxifen were given sequentially and some months apart, cannot be emulated in vitro. This initial study was carried out using combinations of these agents added simultaneously in vitro. Both agents are known to interact with PKC and the initial hypothesis was that both agents may exert their growth-inhibitory effects by interaction with a common isoform or a series of isoforms that are expressed within responsive tumours. In order to examine this, an in vitro study was designed using the bryostatin-sensitive murine P388 cell line and its bryostatin-resistant subclone (P388 BRID), which has been shown to express reduced levels of PKC (Prendiville et al, 1994) .
It was observed that addition of combination of bryostatin 1 and tamoxifen to P388 cells caused increased growth inhibition (Figure 1 ). Tamoxifen can reduce the concentration of bryostatin 1 required to inhibit growth in the P388 cell line by over two orders of magnitude. Similarly, bryostatin 1 can enhance the growthinhibitory effects of tamoxifen by over 30-fold. It is unclear why there is a difference in the magnitude of the synergy (200-fold compared with 30-fold), depending upon which drug is added at the non-inhibitory concentration. Interestingly, the synergistic effect was elicited irrespective of whether the agents were added simultaneously or up to 24 h apart.
Evidence for the involvement of PMA-activated PKC in this synergy is seen in the bryostatin-resistant P388 BRJD cell line. This line has been shown to have reduced (95% reduction) PKC activity and isoenzyme expression (Prendiville et al, 1994) . No synergy was observed in this cell line. Further evidence for the involvement of PKC can be seen through the use of PMA (Table  2 ). This potent activator of PKC enhanced the activity of tamoxifen to a level (25-fold) similar to that for bryostatin 1 (34-fold). However, tamoxifen had only a modest (fourfold) effect on the growth-inhibitory properties of PMA. This difference between PMA and bryostatin 1 is not understood but may arise by modulation of different PKC isoforms or by altered translocation and down-regulation. Bryostatin 1 and PMA have been shown to produce different effects on these processes (Levine et al, 1991; Hocevar et al, 1992; Kennedy et al, 1992) .
The lack of effect of the PKC inhibitor staurosporine on the growth inhibition induced by bryostatin 1 or tamoxifen does not support a role for PKC. However, the complexity and diversity of the PKC family and the cell line-specific effects observed with PKC modulators may explain the lack of effect of this agent.
Under the conditions used in this study, tamoxifen did not induce sensitivity to bryostatin 1 in the MCF-7 and BT-20 cell lines. Thus, it is unlikely that oestrogen receptor status is a major factor in the observed synergy, as neither the MCF-7 nor the BT-20 cell lines (which are classical receptor-positive and receptor-negative cell lines, exhibiting the expected differential effects towards tamoxifen) showed increased sensitivity when treated with combinations of bryostatin 1 and tamoxifen. Further evidence against hormonal involvement is the lack of detectable oestrogen receptor expression in the P388 cell line.
The known interactions of both tamoxifen and bryostatin 1 with PKC make these signalling pathways potential mechanisms underlying this synergy. Treatment of P388 cells with bryostatin 1 and tamoxifen caused large changes in the PMA-activated PKC activity, as determined by incorporation of 32p into the synthetic peptide (Table 3 ). There was a loss of PKC activity 90 min after addition of drugs. This could arise either by tamoxifen-mediated inhibition of PKC or by down-regulation of PKC by bryostatin 1. A similar rapid loss of PKC has been observed in several cell lines after treatment with bryostatin 1 (Kennedy et al, 1992) . A large increase in PKC activity was observed 24 h after treatment with non-toxic levels of bryostatin 1 and tamoxifen. However the use of higher, more growth-inhibitory drug concentrations resulted in a sustained loss of PKC activity. The mechanism underlying these changes in PKC activity is currently under investigation. Work is currently ongoing to determine the fate of individual isoforms of PKC after treatment with these agents.
The potentiation of the growth-inhibitory effects of bryostatin 1 and tamoxifen is large and, if reproduced in other cell lines and more importantly in vivo, may have clinical applications. The present study shows that the P388 cell line, which is sensitive to bryostatin 1, experiences a substantial (200-fold) enhancement of growth inhibition when bryostatin 1 and tamoxifen are used in combination. Preliminary results indicate that PKC may be involved in this synergy. Extrapolation of this experimental study to the clinical observations must be approached with caution, particularly because of the differences in scheduling. Further studies to elucidate the roles of activation and translocation of individual PKC isoforms are needed to fully elucidate the involvement of these enzymes in this process.
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